anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The exploration of naming error patterns in aphasia provides insights into the cognitive processes underlying naming performance. We investigated how semantic and phonological abilities correlate and how they influence naming performance in aphasia. Data from 296 individuals with aphasia, drawn from the Moss Aphasia Psycholinguistics Project Database, were analyzed using a structural equation model. The model incorporated latent variables for semantics and phonology and manifest variables for naming accuracy and error patterns. There was a moderate positive correlation between semantics and phonology after controlling for overall aphasia severity. Both semantic and phonological abilities influenced naming accuracy. Semantic abilities negatively related to semantic, mixed, unrelated errors, and no responses. Interestingly, phonology positively affected semantic errors. Additionally, phonological abilities negatively related to each of phonological and neologism errors. These results highlight the role of semantic and phonological skills on naming performance in aphasia and reveal a relationship between these cognitive processes.
PURPOSE:To obtain the subject new substance, having antimicrobial and antitumor actions and expected as an antimicrobial agent or an anticancer agent by culturing a microorganism, belonging to the genus Streptomyces and capable of producing a substance HP530C2 and collecting the resultant product from a culture. CONSTITUTION:A microorganism [e.g. Streptomyces sp. HP530 strain (FERM P-2786)], belonging to the genus Streptomyces and capable of producing a substance HP530C2 is cultured in a culture medium at 30 deg. for 4 days by shaking culture to prepare a primary seed culture solution, which is then inoculated into a culture medium and cultured at 30 deg. for 4 days by shaking culture to afford a secondary seed culture solution. The resultant culture solution is subsequently inoculated into a jar fermenter and cultured at 30 deg. for 4 days by spinner culture with aeration and the prepared culture solution is then subjected to centrifuging and filtering treatment to immerse a cake containing the microbial cells in acetone and carry out extracting treatment. The obtained extract solution is subsequently concentrated and further subjected to extraction treatment with ethyl acetate. The extract is purified by silica get chromatography to afford the objective new substance HP530C2, expressed by the formula and having antimicrobial and antitumor actions.
The present invention refers to a food supplement for the therapy of surface and invasive cancer of the bladder that can take the form of an extract, or the form of a decoction, or the form of a tablet, depending on the way of production that will be chosen either by the patient or the investor. Specifically the first product arises from the heat treatment of two thousand 2000 mgr. hazelnut shells which are boiled and strained, with the purpose of producing an extract. The extract is placed within glass tubes or waterproof metal containers which are subjected to boiling (benmari) for a period of fifteen to twenty minutes and cooled in order to maintain the mixture. The final product, as described above, and in the quantity of 250 ml, is to be drunk once a day for life. According to the second way of preparation the product arises by rubbing the hazelnut shells to powder and the previously mentioned thermal treatment of 50 gr. Powder in 250 ml water for direct consumption by the patient. The final product, as described above, in the quantity of 250 ml is to be drunk once a day for life. In the end according to the third way of preparation, the product arises through the granulation of the hazelnut shells, as in the second method, and the granules are compressed into tablets. These tablets are covered with polyvinyl pyrolidone (p. v. p.) for the purpose of preventing the hardening of the enclosed with time. It is to be taken once a day for life. The basic advantage present preparation, over the other plant based or chemical based drugs that circulate in the market for the fight against cancer is that hazelnut contains paclitaxel or taxol in cis trans form bound from the a and b tubulin in an equal number of molecule mixture. This means that the mixture with its even number of molecules contains two antipodes which recant each other resulting in the neutralization of the side effects that are caused through the use of common taxol and other material that inhibit the microtubules.
Participants will receive single session training of dual task. Six cognitive games that target working memory, executive functioning, visuomotor reactions, and language fluency will be provided in standing to get themselves familiarized. Following the cognitive tasks, participants will receive 12 slips without performing cognitive task (Single task training) at the highest intensity. Subsequently, 12 slips during standing while performing a cognitive task (dual task) will be administered. Similarly, they will then undergo 12 dual task walking trials (at self-selected speed) followed by 12 walking slips.
Persons with early HIV infection may represent high transmission risk to their partners. Early infection, characterized by rapid virologic replication, insufficient immunologic control of infection, and more rapid course of disease progression, may be associated with increased infectiousness. The viral determinants of transmission may in part be explained by viral burden in blood, genital fluids, and oral cavity fluids. All three fluids may be the source for transmitted virus.

Persons with suspected HIV infection are asked to identify their possible source partners. The importance of partner referral is emphasized and assisted recruitment or active tracing is offered if necessary. Source partners will not be approached uninvited. If a partner states that he/she does not want to be contacted, then he/she will not be contacted further for the purpose of this study or for any other study. All patients are offered HIV counseling and plasma testing for HIV-1 RNA and CD4+ cells. Blood specimens are collected for plasma determination, and cellular and plasma fractions are collected for CAF and neutralization antibodies. Neutralization assays are used to detect humoral immune response in patients with primary HIV infection. Genital fluids and saliva are analyzed for viral RNA. Patients are seen in the clinic on Day 1 for blood draw and return 2 weeks later for blood test results. A follow-up period of at least 4 weeks is planned. Compensation is provided to all patients.
The present invention relates to freeze-dried powder injection of leucovorin sodium and a preparation method thereof. The present invention is the freeze-dried powder injection with leucovorin sodium as main active components and a preparation method for the injection. The injection is the injection obtained by decarbonizing leucovorin, a freeze-dried framework agent and NaOH, or directly stirring leucovorin and NaOH to generate leucovorin sodium which is frozen and dried by a freeze dryer. The preparation method comprises: adding water for injection to the freeze-dried framework agent so as to dissolve the freeze-dried framework agent; adding active carbon for boiling; filtering and decarbonizing; adding leucovorin to prepare a suspension solution; dripping NaOH and stirring the suspension solution for generating leucovorin sodium; mixing the leucovorin sodium with the decarbonized freeze-dried framework agent, or dripping NaOH directly in the leucovorin; adding active carbon; filtering and decarbonizing; filtering a filtering solution by a microporous filtering film; putting obtained products into a cillin bottle in a sterile mode; plugging the obtained products in a half mode and transmitting the obtained products into the freeze dryer for freeze drying; fastening rubber plugs tightly and rolling aluminum caps. The freeze-dried powder injection of the present invention can avoid the decomposition of leucovorin sodium due to high-heat sterilization. The freeze-dried powder injection has the advantages of low water content and stable performance, and is favorable to long term storage. Fine particle substances and pollution chances are few.
The invention relates to a traditional Chinese medicine composition for treating vaginitis and a preparation method thereof. The traditional Chinese medicine composition is prepared from the following raw materials: Sophora alopecuroide total alkali, cortex phellodendri chinensis, radix stemonae, fructus cnidii and fructus cnidii. The traditional Chinese medicine composition is applicable to symptoms such as progenital itch and pain caused by damp-heat type vagina inflammatory diseases. In addition, the invention further provides an extraction method of the traditional Chinese medicine composition containing cortex phellodendri chinensis, radix stemonae and fructus cnidii. The traditional Chinese medicine composition provided by the invention is exact in curative effect in treating damp-heat type vaginitis, and the effect is superior to that of the prior art. According to the extraction method of the traditional Chinese medicine composition, the content of effective components can be increased, and the stability of a final solvent-type product is facilitated, so that the product is better in appearance and quality.
The present invention relates to a process for solubilising keratins from a keratin containing starting material such as poultry feathers. The keratins are may be solubilised using a sulphide under alkaline conditions. In the process the cysteine residues of solubilized keratins and are partially modified, e.g. by alkylation. The conditions of solubilisation and partial modification are chosen such that the keratins are also partially hydrolysed. The partially modified and partially hydrolysed keratin may be used as stable dispersions e.g. for the production of films and coatings by casting.
Tailored lateral sphincterotomy was performed in the lithotomy position by a standard open technique, briefly; a 5-mm incision was made into the perianal skin along the intersphinteric groove. The internal anal sphincter was then dissected and a segment withdrawn with a pair of artery forces and divided with diathermy, the extent of sphincterotomy was done to be more or less equal to the length of the fissure. Then the V-Y advancement flap was performed.
Patients were informed about the study and patients who signed the informed consent form were included in the study. A pretest was applied to the patients. In the pre-test, data were collected using the "Patient Information Form", "Adaptation to Chronic Diseases Scale" and "Beck Anxiety Scale". No application was made to the control group for 1.3 times in 21 days. Posttests were performed at the end of treatment for the third time.
BACKGROUND: Small-molecule inhibitors (SMIs) have revolutionised the treatment of non-small cell lung cancer (NSCLC). However, SMI-induced drug-drug interactions (DDIs) with frequently co-administered direct oral anticoagulants (DOACs), increase thromboembolic and bleeding risks. This study investigated and proactively managed the consequences of DOAC-SMI DDIs.
METHODS: This prospective, observational study enrolled patients with NSCLC concomitantly using a DOAC and SMI. The primary outcome was the proportion of patients with DOAC plasma trough (Ctrough) and peak (Cpeak) concentrations outside expected ranges. Secondary outcomes included DOAC treatment modifications, incidence of bleeding and thromboembolic events and feasibility evaluation of pharmacokinetically guided DOAC dosing.
RESULTS: Thirty-three patients were analysed. Thirty-nine percent (13/33) had DOAC Ctrough and/or Cpeak were outside the expected ranges in 39% (13/33). In 71% (5/7) of patients with DOAC concentrations quantified before and during concurrent SMI use, DOAC Ctrough and/or Cpeak increased or decreased >50% upon SMI initiation. In all patients in whom treatment modifications were deemed necessary, DOAC concentrations were adjusted to within the expected ranges.
CONCLUSION: Proactive monitoring showed that a substantial proportion of patients had DOAC concentrations outside the expected ranges. DOAC concentrations were successfully normalised after treatment modifications. These results highlight the importance of proactive monitoring of DOAC-SMI DDIs to improve treatment in patients with NSCLC.
Pulmonary hypertension (PH) and cardiac dysfunction are established comorbidities of congenital diaphragmatic hernia (CDH). However, there is very little data focusing on arterial hypertension in CDH. This study aims to investigate the incidence of arterial hypertension in neonates with CDH at hospital discharge. Archived clinical data of 167 CDH infants who received surgical repair of the diaphragmatic defect and survived for > 60 days were retrospectively analyzed. Blood pressure (BP) values were averaged for the last 7 days before discharge and compared to standard BP values for sex, age, and height provided by the AHA in 2004. BP values reaching or extending the 95th percentile were defined as arterial hypertension. The use of antihypertensive medication was analyzed at discharge and during hospitalization. Arterial hypertension at discharge was observed in 19 of 167 infants (11.3%) of which 12 (63%) were not receiving antihypertensive medication. Eighty patients (47.9%) received antihypertensive medication at any point during hospitalization and 28.9% of 152 survivors (n = 44) received antihypertensive medication at discharge, although in 45.5% (n = 20) of patients receiving antihypertensive medication, the indication for antihypertensive medication was myocardial hypertrophy or frequency control. BP was significantly higher in ECMO compared to non-ECMO patients, despite a similar incidence of arterial hypertension in both groups (13.8% vs. 10.1%, p = 0.473). Non-isolated CDH, formula feeding, and minimal creatinine in the first week of life were significantly associated with arterial hypertension on univariate analysis. Following multivariate analysis, only minimal creatinine remained independently associated with arterial hypertension.   Conclusion: This study demonstrates a moderately high incidence of arterial hypertension in CDH infants at discharge and an independent association of creatinine values with arterial hypertension. Physicians should be aware of this risk and include regular BP measurements and test of renal function in CDH care and follow-up. What is Known: • Due to decreasing mortality, morbidity is increasing in surviving CDH patients. • Pulmonary hypertension and cardiac dysfunction are well-known cardiovascular comorbidities of CDH. What is New: • There is a moderately high incidence of arterial hypertension in CDH infants at discharge even in a population with frequent treatment with antihypertensive medication. • A more complicated hospital course (ECMO, higher degree of PH, larger defect size) was associated with a higher risk for arterial hypertension.
Genetic screening of newborns for deafness plays an important role in elucidating the etiology of deafness, diagnosing it early, and intervening in it. Genetic screening of newborns has been conducted for 11 years in Beijing. It started with a chip to screen for 9 variants of 4 genes in 2012; the chip screened for 15 variants of those genes in 2018, and it now screens for 23 variants of those genes. In the current study, a comparative analysis of three screening protocols and follow-up for infants with pathogenic variants was performed. The rates of detection and hearing test results of infants with pathogenic variants were analyzed. Subjects were 493,821 infants born at 122 maternal and child care centers in Beijing from April 2012 to August 2023. Positivity increased from 4.599% for the chip to screen for 9 variants to 4.971% for the chip to screen for 15 variants, and further to 11.489% for the chip to screen for 23 variants. The carrier frequency of the GJB2 gene increased from 2.489% for the chip to screen for 9 variants and 2.422% for the chip to screen for 15 variants to 9.055% for the chip to screen for 23 variants. The carrier frequency of the SLC26A4 gene increased from 1.621% for the chip to screen for 9 variants to 2.015% for the chip to screen for 15 variants and then to 2.151% for the chip to screen for 23 variants. According to the chip to screen for 9 variants and the chip to screen for 15 variants, the most frequent mutant allele was c.235delC. According to the chip to screen for 23 variants, the most frequent mutant allele was c.109G>A. The chip to screen for 15 variants was used to screen 66.67% (14/21) of newborns with biallelic variants in the SLC26A4 gene for newly added mutations. The chip to screen for 23 variants was used to screen 92.98% (53/57) of newborns with biallelic variants in the GJB2 gene (52 cases were biallelic c.109G>A) and 25% (1/4) of newborns with biallelic variants in the SLC26A4 gene for newly added mutations. Among the infants with pathogenic variants (biallelic variants in GJB2 or SLC26A4), 20.66% (25/121) currently have normal hearing. In addition, 34.62% (9/26) of newborns who passed the hearing screening were diagnosed with hearing loss. Findings indicate that a growing number of newborns have benefited, and especially in the early identification of potential late-onset hearing loss, as the number of screening sites has increased. Conducting long-term audiological monitoring for biallelic variants in individuals with normal hearing is of paramount significance.
- 27 -An object of the present invention is to provide a lipase activity inhibitor that shows high inhibitory activity against pancreatic lipase to suppress the absorption of meal-derived fat and/or which contributes to suppressing and preventing obesity, as well as a food or beverage that has such lipase activity inhibitor incorporated therein. Another object of the invention is to provide a lipase inhibitor of tea origin that suits most consumers' taste and which will not impair the flavor of the food or beverage when incorporated therein. Still another object of the invention is to provide a process for producing said lipase inhibitors. Further object of the invention is to provide antioxidants. To attain these objects, epigallocatechin diners (oolong homobisflavans) or trimers are incorporated in foods or beverages. As a result, the absorption of meal-derived fat can be suppressed and, in addition, antioxidation effect is obtained. The compounds of the invention can be produced by reacting epigallocatechin gallate with formaldehyde in the presence of an acid.
There will be 48 pregnant or lactating women (PLW) in this arm. They will be randomized to receive cumin flavored LNS-PLW or LNS-PLW with no added flavor on day 2. On day 3, the PLW getting a test-dose of cumin flavored LNS-PLW on day 2 will receive LNS-PLW with no added flavor and the PLW getting a test-dose of LNS-PLW with no added flavor on day 2 will receive cumin flavored LNS-PLW.
PURPOSE: To obtain a dye composition for keratin fiber capable of dyeing hair with air without using an oxidizing agent by compounding an indole dye with at least one paraphenylenediamine containing a secondary amino group. CONSTITUTION: The objective composition is obtained by adding an indole dye of formula I (R1 is H, a lower alkyl, etc.; R2 and R3 are each H, a lower alkyl, carboxyl, etc.; R4 and R5 are each H, a 1-20C alkyl, formyl, a 2-20C acyl, etc.), a paraphenylenediamine of formula II (R12 is H or a lower alkyl; R13 is H, a lower alkyl, a halogen, etc.; R4 is H, a lower alkyl, a lower alkoxy, etc.), in which one of the amino groups is substituted, and its acid-addition salt to an aqueous medium (e.g. alcohol) suitable for dyeing, and further optionally adding a conventional dyeing component. Compounding ratios based on the whole composition are as follows: a compound of formula I is 0.1-5wt.%, a compound of formula II is 0.05-1wt.%, and a solvent is up to 30wt.%.
Subjects with FEV1/FVC score less than 0.70 post-bronchodilator test will be allocated to COPD group and the prevalence of COPD will be evaluated. Subjects in this group will be categorized in 4 groups namely GOLD I - IV depending on the disease severity.
This is an open label multicenter study of P276-00 in subjects with Relapsed and/or Relapsed/Refractory Multiple Myeloma. Cohort of 3 subjects will be enrolled at starting dose of P276-00 which is 50 mg/m2/day to be given intravenously from day 1 to day 5 every 21 days. This 21 day administration constitutes one cycle of P276-00. Six such cycles will be administered to the subjects. If the dose is well tolerated then next cohort will be enrolled at higher dose level of P276-00 till maximum tolerated dose is determined. Safety assessment will be repeated at regular interval and efficacy assessment will be repeated during every cycles.After the subject completes 6 cycles, there will be a follow-up visit after 4 weeks (+1 week) of study completion.Subjects who have stable disease or who have responded (MR, PR or CR) after completion of the 6 cycles will be given the option to continue treatment for a maximum of 12 cycles or until they are deemed to have progressive disease.
A risk factor model of body mass index (BMI) is an important building block of health simulations aimed at estimating government policy effects with regard to overweight and obesity. We created a model that generates representative population level distributions and that also mimics realistic BMI trajectories at an individual level so that policies aimed at individuals can be simulated. The model is constructed by combining several datasets. First, the population level distribution is extracted from a large, cross-sectional dataset. The trend in this distribution is estimated from historical data. In addition, longitudinal data are used to model how individuals move along typical trajectories over time. The model faithfully describes the population level distribution of BMI, stratified by sex, level of education and age. It is able to generate life course trajectories for individuals which seem plausible, but it does not capture extreme fluctuations, such as rapid weight loss.
Participants randomized to this arm will receive a 8 week quit smoking program delivered by trained counselors and messages to their cell phones. Participants will also be offered nicotine replacement therapy (gum or patch, depending on which one is available) and a self-help guide with information about quitting smoking.
After injection with Botulinum Toxin Type A, a schedule of robot-assisted therapy appointments will be established. Each intervention includes 45 minutes of robotic training and 30 minutes of training in functional activities.